Description: BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered development stage programs, including KIACTA for the treatment of sarcoidosis; AMO-01 for treatment of Phelan McDermid syndrome; and ALZ-801 for APOE4 homozygous Alzheimer's disease. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.
Home Page: www.bellushealth.com
BLU Technical Analysis
275 Armand-Frappier Boulevard
Laval,
QC
H7V 4A7
Canada
Phone:
450 680 4500
Officers
| Name | Title |
|---|---|
| Mr. Roberto Francesco Bellini | Pres, CEO & Director |
| Mr. Ramzi Benamar | Chief Financial Officer |
| Dr. Denis Garceau | Chief Scientific Officer |
| Mr. Tony Matzouranis | Sr. VP of Bus. Devel. |
| Dr. Catherine M. Bonuccelli M.D. | Chief Medical Officer |
| Dr. Andreas Orfanos FFPM, M.B.B.Ch, MBA | Chief Operating Officer |
| Mr. Daniel Matthews | Director of Investor Relations & Communications |
| Mr. Francois Desjardins C.A., CPA, CPA, CA | Sr. VP of Fin. |
| Mr. Sebastien Roy | Corp. Sec. |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.0161 |
| Price-to-Sales TTM: | 75790.29 |
| IPO Date: | 2008-12-29 |
| Fiscal Year End: | December |
| Full Time Employees: | 40 |